Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 04, 2016 07:30 ET | Source: Minerva Neurosciences, Inc.

Minerva Neurosciences Reports Second Quarter 2016 Financial Results and Business Updates

Positive clinical data advance development with MIN-101 in schizophrenia and MIN-117 in major depressive disorder Additional trials also planned with MIN-202 in insomnia disorder and major...
July 28, 2016 08:30 ET | Source: Minerva Neurosciences, Inc.

Minerva Neurosciences to Report Second Quarter 2016 Financial Results and Business Updates on August 4, 2016

WALTHAM, Mass., July 28, 2016 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
June 27, 2016 08:30 ET | Source: Minerva Neurosciences, Inc.

Minerva Neurosciences Set to Join Russell 3000® and Russell 2000® Indexes

WALTHAM, Mass., June 27, 2016 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company, today announced that the Company has been added to the...
June 14, 2016 16:15 ET | Source: Minerva Neurosciences, Inc.

Minerva Neurosciences to Present at JMP Securities Life Sciences Conference June 21, 2016

WALTHAM, Mass., June 14, 2016 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat...
June 14, 2016 09:05 ET | Source: Minerva Neurosciences, Inc.

Minerva Neurosciences Announces Pricing of Public Offering of Common Stock

WALTHAM, Mass., June 14, 2016 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company, today announced the pricing of an underwritten public...
June 13, 2016 16:01 ET | Source: Minerva Neurosciences, Inc.

Minerva Neurosciences Announces Proposed Public Offering of Common Stock

WALTHAM, Mass., June 13, 2016 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company, today announced its intention to offer and sell shares of...
June 01, 2016 08:30 ET | Source: Minerva Neurosciences, Inc

Minerva Neurosciences to Present at Jefferies 2016 Healthcare Conference on June 8, 2016

WALTHAM, Mass., June 01, 2016 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat...
May 26, 2016 08:15 ET | Source: Minerva Neurosciences, Inc

Minerva Neurosciences Announces Positive Results in Phase IIA Trial of MIN-117 in Major Depressive Disorder

Reduction in depressive symptoms demonstrated Good tolerability and safety profile observed Positive effect on sleep architecture shown Differentiated mechanism of action WALTHAM,...
May 26, 2016 08:00 ET | Source: Minerva Neurosciences, Inc

Minerva Neurosciences Announces Positive Results From Phase IIB Trial of MIN-101 Monotherapy in Schizophrenia

Statistically significant improvement in PANSS negative symptoms and total PANSS scores observed MIN-101 shown to be statistically superior on key secondary endpoints Effect of MIN-101...
May 03, 2016 07:30 ET | Source: Minerva Neurosciences, Inc

Minerva Neurosciences Reports First Quarter 2016 Financial Results and Business Updates

Positive top line results of trials with MIN-202 highlight first quarter Last patient visits completed in trials with MIN-101 and MIN-117; data expected in second quarter WALTHAM, Mass., May 03,...